Clinical trial · Interventional
18F-fluorocholine and 18F-fluoride PET in Prostate Cancer
Comparative Evaluation of Metastatic Lesions From Prostate Carcinoma With 18F-NaF and 18F-Fluorocholine PET/CT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancer remains to be a public health problem around the world. For patients with prostate cancer, diphosphonate bone scintigraphy (BS) and pelvic tomographic imaging are major imaging tools to evaluate the disease spread. However, the conventional image modalities have only limited sensitivity and specificity. New imaging tracer with 18F-fluorocholine (18F-FCH) and old radiopharmaceuticals with NaF has showed promising results in detecting prostate cancers over bone scan. Nevertheless, the diagnostic performance of each tool has less been compared. The goal of this study is to compare the diagnostic performance of 18F-FCH PET/CT and NaF PET/CT for prostate cancer patients. The investigators prospectively enroll patients with the pathological diagnosis of prostate cancer and intended to receive radionuclide bone image. The patients will receive NaF PET/CT and 18F-FCH PET/CT. Each image will be evaluated by experienced interpreter for abnormal uptake suspicious for cancer spreading. The reference standard will be a combination of tissue correlation, imaging, laboratory and clinical data. Diagnostic performance of both PET/CT scans will be measured and calculated.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fluorocholine | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-fluorocholine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-fluorocholine PET/CT
- description
- 18F-fluorocholine PET/CT
- interventionNames
- Drug: 18F-fluorocholine
Primary outcomes (2)
- measure
- The sensitivities of 18F-fluorocholine PET/CT and NaF PET/CT
- timeFrame
- 6 weeks
- description
- The lesion-based sensitivities of these two image modalities (The number of true positive image findings/The number of confirmed metastasis)
- measure
- The specificities of 18F-fluorocholine PET/CT and NaF PET/CT
- timeFrame
- 6 weeks
- description
- The lesion-based specificities of these two image modalities (The number of true negative image findings/The number of confirmed e benign lesion)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients are pathologically diagnosed with prostate adenocarcinoma. * Received NaF PET/CT. Exclusion Criteria: * Diagnosed to have multiple cancers * Younger than 20-year-old * Known allergic to investigational drug * The patients is classified as not suited for the exam by the investigators.
References
Publications (0)
Data not yet available